Aldeyra The


Prices are adjusted according to historical splits.

Aldeyra The Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$425.73 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Aldeyra The had its IPO on 2014-05-02 under the ticker symbol ALDX.

The company operates in the Healthcare sector and Biotechnology industry. Aldeyra The has a staff strength of 15 employees.

Stock update

Shares of Aldeyra The opened at $9.45 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $9.18 - $9.55, and closed at $9.5.

This is a +0.53% increase from the previous day's closing price.

A total volume of 771,490 shares were traded at the close of the day’s session.

In the last one week, shares of Aldeyra The have increased by +17.87%.

Aldeyra The's Key Ratios

Aldeyra The has a market cap of $425.73 million, indicating a price to book ratio of 2.2385 and a price to sales ratio of 0.

In the last 12-months Aldeyra The’s revenue was $0 with a gross profit of $0 and an EBITDA of $-64134104. The EBITDA ratio measures Aldeyra The's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aldeyra The’s operating margin was 0% while its return on assets stood at -18.42% with a return of equity of -33.98%.

In Q3, Aldeyra The’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Aldeyra The’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aldeyra The’s profitability.

Aldeyra The stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0754. Its price to sales ratio in the trailing 12-months stood at 0.

Aldeyra The stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$189.69 million
Total Liabilities
$24.20 million
Operating Cash Flow
$19.02 million
Capital Expenditure
Dividend Payout Ratio

Aldeyra The ended 2023 with $189.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $189.69 million while shareholder equity stood at $162.19 million.

Aldeyra The ended 2023 with $0 in deferred long-term liabilities, $24.20 million in other current liabilities, 58560.00 in common stock, $-343814476.00 in retained earnings and $0 in goodwill. Its cash balance stood at $128.65 million and cash and short-term investments were $185.33 million. The company’s total short-term debt was $12,633,657 while long-term debt stood at $3.30 million.

Aldeyra The’s total current assets stands at $189.48 million while long-term investments were $0 and short-term investments were $56.68 million. Its net receivables were $21.50 million compared to accounts payable of $1.31 million and inventory worth $0.

In 2023, Aldeyra The's operating cash flow was $19.02 million while its capital expenditure stood at $0.

Comparatively, Aldeyra The paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Aldeyra The stock is currently trading at $9.5 per share. It touched a 52-week high of $7.99 and a 52-week low of $7.99. Analysts tracking the stock have a 12-month average target price of $19.88.

Its 50-day moving average was $7.12 and 200-day moving average was $6.08 The short ratio stood at 6.44 indicating a short percent outstanding of 0%.

Around 234.9% of the company’s stock are held by insiders while 6010% are held by institutions.

Frequently Asked Questions About Aldeyra The

The stock symbol (also called stock or share ticker) of Aldeyra The is ALDX

The IPO of Aldeyra The took place on 2014-05-02

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.


131 Hartwell Avenue, Lexington, MA, United States, 02421